{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-skin/management/management/","result":{"pageContext":{"chapter":{"id":"187d27a6-4a3a-59f4-99c1-33a221ca0d2b","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field e952803f-8e36-4beb-a3a0-b35f02194a49 --><h2>Scenario: Management of skin candida</h2><!-- end field e952803f-8e36-4beb-a3a0-b35f02194a49 -->","summary":"Covers the primary care management of people with candidal skin infections.","htmlStringContent":"<!-- begin item 8d4e4d99-0a12-4a75-bff8-900e8131f099 --><!-- begin field 193e56b8-203d-4984-952d-acbc01587893 --><p>From age 1 month onwards.</p><!-- end field 193e56b8-203d-4984-952d-acbc01587893 --><!-- end item 8d4e4d99-0a12-4a75-bff8-900e8131f099 -->","topic":{"id":"0d4d1ca9-1f95-59a6-9163-91faf2fce35e","topicId":"44d93cc7-56e9-4f35-92ee-6fe5c97d5646","topicName":"Candida - skin","slug":"candida-skin","lastRevised":"Last revised in May 2017","chapters":[{"id":"fdd77154-68fd-5e12-ab34-4980d82ec2e8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"20e27b79-2755-56d0-811f-79d59b1ad973","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"dc171785-2e5e-50c2-9f57-0cd56c75a2d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"9ce37f9c-5801-5953-acaa-da119b97818f","slug":"changes","fullItemName":"Changes"},{"id":"a9f51671-bb82-536e-9b5f-c98cb41291e6","slug":"update","fullItemName":"Update"}]},{"id":"6f439137-5e54-571e-b7aa-8cce9c5c58f6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7433f221-a6d1-5f98-a53d-32009abd6d65","slug":"goals","fullItemName":"Goals"},{"id":"c1df0f9d-1fa3-5aa3-96a3-7636250c141a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1edcd62f-0185-5317-a25a-afb5e18d3d5e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e514a54c-ae49-5bb6-9c8e-0de16f244409","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00336847-83a8-540e-954e-23801c8eb472","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"99dacab6-3fed-5a48-ad05-74876122fa41","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7884dd9b-ba26-56fe-8b96-29022de73f28","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3aa00866-7e3b-5a84-9b01-091a915acd1e","slug":"definition","fullItemName":"Definition"},{"id":"82ae2b5c-db02-50a0-9572-a12b245c9f9f","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"16b02723-03c7-5877-8f98-955d9ba0adda","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"3e942288-d611-5acc-a0a5-79c5a9bbf5c3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"815a9379-3ee5-585a-997e-8daf2e138d95","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"556293f9-6cf5-5f40-bdd2-06dfff1c5b82","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d48752d8-0979-5908-b55c-40d0bf50e947","fullItemName":"Management","slug":"management","subChapters":[{"id":"187d27a6-4a3a-59f4-99c1-33a221ca0d2b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ab1b23e6-6d8b-5003-bdea-20df2a09e2b1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"216d1aaa-ae60-548d-b753-0c53f672a4ad","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"a6376d8b-e282-52b4-a990-ceb7d73afaf3","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"}]},{"id":"1b822a63-5645-5cdc-9a82-7e61da577351","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6bcfeaf8-f78c-5867-99f3-adb4fde508db","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e9a0750e-9090-547a-aac2-eea9118c16c8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7624a8b0-8f03-5842-b47f-0374a546f628","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e3980da9-5b2b-5ebb-a7ed-7edcff958155","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3941da5-da7c-5313-b272-7df5b0bd2985","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0839e574-758e-59d0-8520-6335161c5e49","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3603b783-48c3-58d3-a191-1fb1ff30eca8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d48752d8-0979-5908-b55c-40d0bf50e947","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"3f2ebca4-b1d7-5372-bde8-846e48ce862a","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field b33fbf51-1fc9-4edf-8c73-2975e92395dc --><h3>How should I manage a person with candidal skin infection?</h3><!-- end field b33fbf51-1fc9-4edf-8c73-2975e92395dc -->","summary":null,"htmlStringContent":"<!-- begin item 03cf6c95-bd42-4b20-b997-284eaf218cf4 --><!-- begin field eadb30e2-d8af-4845-8f0a-70867c54fa78 --><ul><li><strong>Admit the person to hospital if <a class=\"topic-reference internal-reference\" href=\"/topics/candida-skin/background-information/complications-prognosis/\">systemic candidiasis</a></strong> is suspected (for example there is peritonitis or meningitis).</li><li><strong>If the infection is not widespread and the person is not significantly immunocompromised, </strong>prescribe a topical antifungal treatment.<ul><li><strong>For an adult,</strong> prescribe a topical imidazole (clotrimazole, econazole, miconazole, or ketoconazole) or terbinafine.</li><li><strong>For a child, </strong>prescribe topical clotrimazole, econazole, or miconazole.</li><li>See the prescribing information section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-skin/prescribing-information/topical-antifungals/\">Topical antifungals</a> for information on prescribing these treatments, including information on the frequency and duration of use.</li></ul></li><li><strong>If inflammation or itch is particularly problematic</strong><strong>,</strong> consider prescribing a mildly potent corticosteroid cream (for example hydrocortisone 1%) in addition to the topical antifungal. <ul><li>Advise that the topical corticosteroid should be used once or twice a day for 7 days.</li><li>Review the person after 7 days of treatment.<ul><li><strong>If symptoms have resolved,</strong> stop the corticosteroid.</li><li><strong>If there has been a significant improvement in symptoms,</strong> continue the corticosteroid for a further 7 days.</li><li><strong>If there is no response to treatment,</strong> discontinue corticosteroid treatment and <a class=\"topic-reference internal-reference\" href=\"/topics/candida-skin/diagnosis/differential-diagnosis/\">reassess the diagnosis</a>. Consider seeking specialist advice where there is uncertainty.</li></ul></li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for detailed information on prescribing topical corticosteroids.</li></ul></li><li><strong>If </strong><strong>topical treatment is not effective, </strong><strong>the infection is widespread, or the person is significantly immunocompromised:</strong><ul><li><strong>For adults and children aged 16 years and older, </strong>treat with oral fluconazole 50 mg a day for 2 weeks then review response to treatment.<ul><li><strong>If the infection has completely resolved, </strong>stop treatment.</li><li><strong>If the infection has not completely resolved, </strong>consider the following: extending the course of fluconazole for a further 2 weeks (refer to a dermatologist if the infection persists after this); swabbing to identify the causative organism; seeking specialist advice; or referring to a dermatologist — use clinical judgement, taking into account the severity of infection (there should be a low threshold for early referral if infection is severe), the level of immunocompromise, and the response to treatment. </li></ul></li><li><strong>For children younger than 16 years of age, or if fluconazole is contraindicated, </strong>seek specialist advice.</li><li>See the prescribing information section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-skin/prescribing-information/oral-fluconazole/\">Fluconazole</a> for information on prescribing this treatment, including the contraindications, cautions, adverse effects, and key drug interactions.</li></ul></li><li><strong>Offer appropriate advice to aid healing and prevent recurrence. </strong>In particular:<ul><li>Advise the person to avoid skin occlusion when possible (for example tight clothing and non-breathable fabrics), and to change dressings, incontinence pads, or nappies (in babies) before they become saturated.</li><li>Advise the person to wash skin regularly with a soap substitute (for example emulsifying ointment) and ensure skin is dried adequately afterwards, especially in the skin folds.</li><li>If obesity is a contributing factor, offer advice on weight loss. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li></ul></li><li><strong>Refer to a dermatologist if:</strong><ul><li>There is widespread or recurrent infection for which an underlying cause has not been identified in primary care.</li><li>The diagnosis is uncertain.</li></ul></li></ul><!-- end field eadb30e2-d8af-4845-8f0a-70867c54fa78 --><!-- end item 03cf6c95-bd42-4b20-b997-284eaf218cf4 -->","subChapters":[{"id":"631238e8-c850-5fcc-aca4-f525f073469e","slug":"basis-for-recommendation-395","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b8576429-14d3-45e6-ba29-8818f72ad7a1 --><h4>Basis for recommendation</h4><!-- end field b8576429-14d3-45e6-ba29-8818f72ad7a1 -->","summary":null,"htmlStringContent":"<!-- begin item 395d94f4-8cbc-41b6-acc1-8fec463d9e8a --><!-- begin field e08a9aa4-5d28-4713-90e6-2e2f52a24e56 --><h5>Arranging admission if systemic candidiasis is suspected </h5><ul><li>This recommendation is based on the fact that systemic/invasive candidiasis is a significant cause of morbidity and mortality. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-skin/background-information/complications-prognosis/\">Complications and prognosis</a> for more information.</li></ul><h5>Topical antifungal treatment</h5><ul><li>CKS found little published evidence on the treatment of candidal skin infections. However, topical imidazoles are widely considered to be effective and are recommended in the Primary Care Dermatology Society (PCDS) guideline on <em>Intertrigo</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Primary Care Dermatology Society, 2016b</a>], review articles on skin infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Evans and Gray, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Laube, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Kalra, 2014</a>], and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">BNF 72, 2016</a>]. In addition, they are licensed for the treatment of fungal skin infections.<ul><li>Clotrimazole, econazole, and miconazole are licensed for use in adults and children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI, 2015b</a>].</li><li>Topical ketoconazole is licensed for adult use only [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI Medicines Compendium, 2015b</a>].</li></ul></li><li>Topical terbinafine is licensed for the treatment of fungal skin infections in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI Medicines Compendium, 2016a</a>].</li></ul><h5>Managing problematic inflammation or itch</h5><ul><li>The recommendation to consider a mildly potent topical corticosteroid to alleviate inflammation and pruritus is based on expert opinion in the American Academy of Dermatology (AAD) <em>Guidelines of care for superficial mycotic infections of the skin: mucocutaneous candidiasis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">American Academy of Dermatology, 1996</a>] and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Laube, 2004</a>].</li><li>The recommended duration of treatment is based on feedback from previous expert reviewers of this CKS topic, bearing in mind the potential for adverse effects (for example skin thinning and striae) with prolonged use.</li><li>Some experts recommend that topical corticosteroids should not be used alone because they increase the risk of fungal proliferation, worsening of symptoms, and the development of tinea incognito (an atypical skin appearance due to local corticosteroid application, which may mask true dermatophyte infection) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Erbagci, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Gupta et al, 2004</a>].</li></ul><h5>Managing treatment failure, widespread infection, and people who are significantly immunocompromised</h5><ul><li><strong>Managing people aged 16 years and older</strong><ul><li>A number of review articles discussed the place of systemic treatments in managing candidal skin infections and concluded that they should not be routinely used, although there are situations in which they may be appropriate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Evans and Gray, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Laube, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Janniger et al, 2005</a>]; CKS has listed these criteria. </li><li>Fluconazole has a broad range of antifungal activity, including against <em>Candida</em> species. It is given orally for infections that do not respond to topical treatment (or when topical treatment cannot be used) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">BNF 72, 2016</a>].<ul><li> The recommended dose and duration of fluconazole are based on the manufacturer's Summary of Product Characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI, 2015c</a>] and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">BNF 72, 2016</a>], which recommend 50 mg daily (100 mg daily in unusually difficult infections) given for 14–28 days.</li></ul></li><li>For managing treatment failure, CKS recommends using clinical judgement to decide whether to give another course of fluconazole, swab to identify the causative organism, seek specialist advice, or refer to a dermatologist, taking into account the severity of infection, the level of immunocompromise, and the response to treatment. </li><li>The recommendation to consider swabbing is based on expert opinion in review articles, which state that:<ul><li>If there is no improvement after antifungal treatment, bacterial culture and sensitivity tests should be performed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Janniger et al, 2005</a>].</li><li>Drug-resistant strains of <em>Candida albicans</em> and related species have been reported, especially in immunosuppressed people and people managed with prophylactic antifungal preparations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Evans and Gray, 2003</a>].</li><li>A skin swab is recommended if there is clinical suspicion of secondary bacterial infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Laube, 2004</a>].</li></ul></li><li>If management in primary care with a topical imidazole followed by oral fluconazole has not been successful, CKS advises considering referral to a dermatologist to ensure that the diagnosis is correct and for consideration of further treatment which is more appropriate to a secondary care setting. </li></ul></li><li><strong>Managing children younger than 16 years of age</strong><ul><li>CKS recommends seeking specialist advice in children younger than 16 years of age because if topical treatment is not effective, the infection is widespread, or the child is immunosuppressed, assessment in secondary care may be more appropriate.</li></ul></li></ul><h5>Offering appropriate advice to aid healing and prevent recurrence</h5><ul><li><p>These recommendations are based on expert opinion in the PCDS guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Primary Care Dermatology Society, 2016b</a>] and in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Evans and Gray, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Laube, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">Kalra, 2014</a>].</p></li></ul><h5>Referral</h5><ul><li>The additional recommendations on when to refer people with candidal skin infections are based on what CKS considers to be good clinical practice. <ul><li>People with widespread or recurrent infection may have underlying predisposing factors (for example immunocompromise) which require investigation and may need further treatment only available in secondary care.</li></ul></li></ul><h5>Treatments not recommended</h5><ul><li><strong>Griseofulvin, itraconazole, and oral terbinafine</strong> are not licensed to treat candidal infections of the skin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">BNF 72, 2016</a>]. </li><li><strong>Oral ketoconazole </strong>should no longer be prescribed for the treatment of fungal infections as the risk of liver damage outweighs the benefits. For this reason, the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has suspended its marketing authorisation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">MHRA, 2013</a>]. See the <a href=\"http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON297530\" data-hyperlink-id=\"c1d20665-7efd-44fd-a47a-a98c01883c86\">MHRA website</a> for more information.</li><li><strong>Combination products containing clotrimazole plus hydrocortisone and miconazole plus hydrocortisone </strong>are available (and are licensed) for the treatment of fungal skin infections with co-existing inflammation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">BNF 72, 2016</a>]. However, CKS does not recommend these products because they are licensed to be used once or twice a day for a maximum of seven days, but topical antifungal treatment is usually required for a longer period. Prescribing a topical corticosteroid separately to the topical antifungal allows the corticosteroid to be used once or twice a day for the initial recommended duration of 7 days, and the antifungal treatment to be continued for the recommended frequency and duration.</li></ul><!-- end field e08a9aa4-5d28-4713-90e6-2e2f52a24e56 --><!-- end item 395d94f4-8cbc-41b6-acc1-8fec463d9e8a -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}